SecBot SecBot
SECBOTREPLAY Home › Report › MRKR

MRKR · Marker Therapeutics reported its 2025 financial results and provided…

Marker Therapeutics, Inc. · 8-K filed Mar 19, 2026 at 06:00 ET

At the news

MIXEDIMPACT 6/10

8-K filed Mar 19, 2026 at 06:00 ET

Marker Therapeutics reported its 2025 financial results and provided clinical updates, highlighting a 66% objective response rate in relapsed non-Hodgkin lymphoma from its APOLLO study and promising pancreatic cancer research published in Nature Medicine. The company ended 2025 with $17 million in cash, sufficient to fund operations through Q4 2026, while R&D expenses decreased to $11.8 million. The stock has a market cap of $22 million.

  • 66% objective response rate (8/12 patients) in relapsed non-Hodgkin lymphoma with MT-601 therapy, including 50% complete responses
  • 78% objective response rate (7/9 patients) in Hodgkin lymphoma
  • Nature Medicine publication showed up to 84.6% disease control rate in pancreatic cancer when combined with chemotherapy
  • Cash position of $17 million at year-end 2025, expected to fund operations through Q4 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access